Related Experiment Video
Updated: May 20, 2026
12:07
Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer
Published on: November 18, 2022
Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Stefano Crippa1, Stefano Partelli, Giuseppe Zamboni
1Department of Surgery, University of Verona, Verona, Italy. ste.crippa@libero.it
Surgery
|July 7, 2012
Summary
Poorly differentiated pancreatic cancer (G3 PDAC) shows worse survival and benefits more from adjuvant therapy. These findings suggest G3 PDAC patients may benefit from neoadjuvant treatment before surgery.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) with poor differentiation (G3) is linked to early recurrence.
- Neoadjuvant treatment may improve outcomes for resectable PDAC.
Purpose of the Study:
- To evaluate clinicopathologic features and survival in resectable PDAC patients based on histologic grading.
- To determine the impact of histologic grade on treatment response and prognosis.
Main Methods:
- Analysis of 502 patients who underwent resection for PDAC between 1990 and 2008.
- Histologic grading (G1, G2, G3) was used to categorize tumors and assess outcomes.
Main Results:
- G3 PDAC (33.5% of cases) exhibited significantly lower disease-specific survival (20 months) and disease-free survival (9 months) compared to G1 and G2.
- G3 tumors were associated with more lymph node metastases, invasion, and incomplete resections (R2).
- Adjuvant therapy significantly improved survival, with a greater benefit observed in G3 PDAC patients.
Conclusions:
- G3 PDAC is associated with poorer survival and adverse prognostic factors post-resection.
- The survival benefit of adjuvant therapy is more pronounced in G3 PDAC.
- Resectable G3 PDAC patients are potential candidates for neoadjuvant treatment strategies.
